Tranexamic Acid & Kojic Acid
— When Tyrosinase Inhibition Meets pH Drift
Two of the most potent brightening ingredients mechanistically complement each other in addressing the melanogenesis signaling pathway — yet their combination often fails in practice due to a single parameter: the pH of the formulation.
Tranexamic acid and kojic acid are among the most intensely researched brightening ingredients in modern cosmetic chemistry — yet their interaction in complex formulations presents formulators with challenges that extend far beyond mere active ingredient concentration. In particular, the superposition of two different tyrosinase inhibition pathways with simultaneous pH sensitivity of one of the active ingredients creates a tension that is increasingly discussed in the literature.
The enzyme tyrosinase is considered a central hub of melanin synthesis: it catalyzes both the hydroxylation of L-tyrosine to L-DOPA and the subsequent oxidation to DOPAquinone — two steps crucial for skin hyperpigmentation. Tranexamic acid and kojic acid address this signaling pathway in mechanistically different ways, theoretically opening up synergistic potential, but in practice limited by pH-dependent stability thresholds. Understanding these relationships is essential for evidence-based moisturizing care and active ingredient formulation.
Plasmin Axis, Copper Chelation, and pH Drift: Two Points of Attack, One Collision
The two active ingredients differ not only in their chemical structure but fundamentally in the section of the melanogenesis pathway they target. While tranexamic acid primarily acts on upstream signaling cascades, kojic acid directly inhibits the copper center of tyrosinase. This mechanistic diversity is the core of their potential combination relevance — but also the cause of their formulation incompatibility.
Tranexamic acid (TXA) is structurally a lysine analog and competitively inhibits the binding of plasminogen to keratinocytes. This reduces the release of arachidonic acid and subsequent prostaglandin E2 production. Since prostaglandin E2 stimulates melanocytes to increased tyrosinase expression via cAMP signaling pathways, TXA acts indirectly — by interrupting paracrine keratinocyte-melanocyte crosstalk. Additionally, TXA can be associated in the literature with a reduction of ACTH-like stimuli of melanogenesis, which appears particularly relevant for UV-induced hyperpigmentation.
Kojic acid (5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one) is a natural product from the fermentation of Aspergillus and Penicillium strains. Its inhibitory effect is based on the chelation of Cu²⁺ ions in the active center of tyrosinase — a direct, non-competitive mechanism. Without a functional copper cofactor system, tyrosinase cannot efficiently catalyze either the monophenolase or diphenolase reaction. In formulation chemistry, kojic acid is also considered a free radical scavenger, which, beyond pure tyrosinase inhibition, introduces an antioxidant component into the brightening strategy — relevant in the context of free radicals.
Here lies the real complexity hurdle of brightening combinations: tranexamic acid, as a zwitterionic compound, is stable and effective over a wide pH range (4.0–8.0). Kojic acid, however, is pH-sensitive and increasingly oxidizes at values above pH 5.5 — it turns brownish and loses its chelating ability. Formulations designed for optimal skin homeostasis at pH 5.0–5.5 are precisely in the borderline range of kojic acid stability. If the pH shifts slightly upwards during the production process or due to raw material interactions, a significant loss of efficacy can occur without being immediately visually recognizable.
Yellowing and Loss of Efficacy Masquerade as Mere Irritation
The true potential of tranexamic acid-kojic acid combinations lies in their mechanistic complementarity: pre-tyrosinase (TXA) and direct-enzymatic (kojic acid). However, this synergy is only achievable if the pH is precisely stabilized at ≤ 5.2 and kojic acid is protected against oxidative degradation by suitable antioxidants — for instance, in combination with ferulic acid or vitamin C derivatives. Without this stability management, the formulation effectively degenerates into a mono-substance.
pH Precision: Oxidation Protection as a Prerequisite for the Stability of Both Active Ingredients
- pH-controlled formulations at 4.8–5.2, consistently stabilized by suitable buffer systems
- Light-protected packaging (airless, opaque) to protect kojic acid from UV-induced oxidation
- Combination with stabilized antioxidants such as ferulic acid or tocopherol derivatives for degradation prevention
- Simultaneous use of highly alkaline skincare products that destabilize the formulation pH
- Storage at high temperatures or direct sunlight
- Combination with strongly chelating agents that can competitively affect the kojic acid-copper bond
The NATURFACTOR® Porcelain Skin Serum supports chrono-optimized daily care with a pH-stabilized brightening approach: the Bioactive Infusion Complex™ is designed for precise active ingredient stability, avoiding precisely those formulation pitfalls described in the literature for unstable brightening combinations. For nighttime, the Blue Crystal Drops complement the routine with a formulation strategy adapted to the nocturnal skin repair rhythm — because melanogenesis, like many enzymatic skin processes, exhibits a pronounced circadian activity dynamic that is increasingly relevant for formulation within the context of skin chronobiology. Careful exfoliation routines can additionally help optimize the penetration depth and bioavailability of brightening active ingredients without compromising barrier function.
For specific skin concerns – such as persistent irritation, chronic hyperpigmentation, or suspected contact sensitization from kojic acid-containing products – a medical evaluation by a dermatologist should be sought.
Frequently Asked Questions
Can tranexamic acid and kojic acid be used simultaneously in a formulation?
Basically, yes — both active ingredients are chemically compatible. However, the critical challenge lies in pH stabilization: Only at a precisely controlled pH below 5.2 does kojic acid remain stable enough to exert its tyrosinase-inhibiting effect. Without appropriate stability management, the synergistic potential of the combination is often not fully achievable in practice.
How do I know if kojic acid in my product has degraded?
A clear sign is a yellowish-brown discoloration of the product. Fresh, stable kojic acid is almost colorless to slightly yellowish; a pronounced browning indicates oxidative degradation. A changed odor can also be an indicator. Products in opaque, airtight packaging are generally more stable.
Does tranexamic acid also work on hyperpigmentation without kojic acid?
Yes. Tranexamic acid, as a single substance, shows reproducible effects on UV-induced hyperpigmentation in the literature, especially in melasma. Its indirect mechanism of action via the plasmin-prostaglandin axis makes it a well-tolerated brightening active that can also be formulated without combination with direct tyrosinase inhibitors. More on evidence-based anti-aging care can be found in our knowledge database.
What role does the Fitzpatrick skin type play in the effectiveness of brightening complexes?
Melanocyte activity varies significantly between Fitzpatrick types. Darker skin types (IV–VI) structurally produce more eumelanin and often show higher baseline tyrosinase activity — which increases the demands on the brightening formulation. At the same time, sensitivity to irritating brightening ingredients is often increased in this group. Gentler, mechanistically diversified approaches — such as the combination of TXA with stabilized tyrosinase inhibitors — can be discussed as advantageous in the literature.
- Chaowattanapanit, S. et al. (2017). Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention. Journal of the American Academy of Dermatology, 77(4), 591–605.
- Saeedi, M., Eslamifar, M. & Khezri, K. (2019). Kojic acid applications in cosmetic and pharmaceutical preparations. Biomedicine & Pharmacotherapy, 110, 582–593.
- Ebrahimi, B. & Naeini, F. F. (2014). Topical tranexamic acid as a promising treatment for melasma. Journal of Research in Medical Sciences, 19(8), 753–757.
- Passeron, T. & Picardo, M. (2018). Melasma, a photoaging disorder. Pigment Cell & Melanoma Research, 31(4), 461–465.
- Pillaiyar, T., Manickam, M. & Namasivayam, V. (2017). Skin whitening agents: Medicinal chemistry perspective of tyrosinase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 32(1), 403–425.
This article is for informational purposes only and does not constitute medical advice. For specific skin concerns, we recommend consulting a dermatologist.
